Company news

Passage Bio, Inc. news in 2022

Passage Bio, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

December 13, 2022

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 9, 2022

Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day

November 7, 2022

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

November 2, 2022

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 13, 2022

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

October 9, 2022

Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 25, 2022

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

August 18, 2022

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

August 10, 2022

Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

August 4, 2022

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights

August 3, 2022

Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

July 27, 2022

Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors

July 5, 2022

Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

June 8, 2022

Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

June 7, 2022

Passage Bio Announces Leadership Transition

May 31, 2022

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2022

Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting

May 17, 2022

Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights

May 15, 2022

Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022

May 8, 2022

Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

May 1, 2022

Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

March 28, 2022

Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway

March 14, 2022

Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric Condition

March 9, 2022

Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

March 2, 2022

Passage Bio to Participate in Upcoming March Investor Conferences

February 28, 2022

Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

February 23, 2022

Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium

February 10, 2022

Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11

January 30, 2022

Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline

January 9, 2022

Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Calls in 2022

Decks in 2022